Matthew JL Hare

MBBS (Hons), BMedSc (Hons), FRACP, Endocrinologist, Department of Endocrinology, Royal Darwin Hospital, Darwin, NT; Senior Research Officer, Menzies School of Health Research, Charles Darwin University, Darwin, NT

Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Numerous glucose-lowering medications have been developed in recent years with growing evidence relating to their efficacy and safety.

Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes

Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.